NCT04464629View on ClinicalTrials.gov

Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment

PHASE4TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

January 25, 2023

Study Completion Date

January 25, 2023

Conditions
Retinal Detachment
Interventions
DRUG

Dextenza

Intracanalicular sustained release dexamethasone insert 0.4 mg

DRUG

Prednisolone Acetate

Topical Prednisolone acetate 1% ophthalmic suspension

Trial Locations (1)

46290

Midwest Eye Institute, Indianapolis

Sponsors

Collaborators (1)

Ocular Therapeutix, Inc.
All Listed Sponsors
collaborator

Ocular Therapeutix, Inc.

INDUSTRY

lead

Midwest Eye Institute

OTHER